{"id":"u0267-foam","safety":{"commonSideEffects":[{"rate":null,"effect":"Local skin irritation"},{"rate":null,"effect":"Burning or stinging at application site"},{"rate":null,"effect":"Skin atrophy (with prolonged use)"}]},"_chembl":{"chemblId":"CHEMBL2107974","moleculeType":"Small molecule"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As a foam formulation, U0267 delivers corticosteroid active ingredient in a lightweight, spreadable vehicle that enhances skin penetration and patient compliance. The corticosteroid component works by suppressing inflammatory cytokines and immune cell activity at the site of application, reducing erythema, pruritus, and other inflammatory skin manifestations.","oneSentence":"U0267 Foam is a topical corticosteroid formulation designed to reduce inflammation and provide therapeutic benefit when applied directly to affected skin areas.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:51:51.628Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory skin conditions (specific indication under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT00688519","phase":"PHASE3","title":"Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-03","conditions":"Psoriasis","enrollment":336},{"nctId":"NCT00689481","phase":"PHASE3","title":"Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-03","conditions":"Psoriasis","enrollment":323}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"U0267 Foam","genericName":"U0267 Foam","companyName":"Stiefel, a GSK Company","companyId":"stiefel-a-gsk-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"U0267 Foam is a topical corticosteroid formulation designed to reduce inflammation and provide therapeutic benefit when applied directly to affected skin areas. Used for Inflammatory skin conditions (specific indication under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}